File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/00001756-199512000-00041
- Scopus: eid_2-s2.0-0029551796
- PMID: 8742444
- WOS: WOS:A1995TX36900041
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Association between clozapine response and allelic variation in the 5-HT(2C) receptor gene
Title | Association between clozapine response and allelic variation in the 5-HT(2C) receptor gene |
---|---|
Authors | |
Keywords | 5-HT2c receptor Amino acid substitution Association study Clozapine Genotype Schizophrenia |
Issue Date | 1995 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.neuroreport.com |
Citation | Neuroreport, 1995, v. 7 n. 1, p. 169-172 How to Cite? |
Abstract | A cysteine to serine substitution at amino acid 23 in the 5-HT(2C) receptor gene alters the pharmacological properties of the protein. We investigated this polymorphism in subjects with schizophrenia resistant to conventional neuroleptic drugs, and analysed our data for allelic association between the disease state or clinical response to the atypical antipsychotic drug, clozapine. Ninety percent of subjects who had one or more 5-HT(2C)ser alleles (19/21) were classified as clozapine responders compared with 59% (84/141) without this allele (χ2 = 7.7, p = 0.005), suggesting that this mutation is a predictor of good response to clozapine. There was no association between schizophrenia and the 5-HT(2C)ser allele, but our results indicate that the 5-HT(2C) receptor may contain the major site of action through which clozapine mediates its antipsychotic effects. |
Persistent Identifier | http://hdl.handle.net/10722/175736 |
ISSN | 2023 Impact Factor: 1.6 2023 SCImago Journal Rankings: 0.459 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sodhi, MS | en_US |
dc.contributor.author | Arranz, MJ | en_US |
dc.contributor.author | Curtis, D | en_US |
dc.contributor.author | Ball, DM | en_US |
dc.contributor.author | Sham, P | en_US |
dc.contributor.author | Roberts, GW | en_US |
dc.contributor.author | Price, J | en_US |
dc.contributor.author | Collier, DA | en_US |
dc.contributor.author | Kerwin, RW | en_US |
dc.date.accessioned | 2012-11-26T09:00:51Z | - |
dc.date.available | 2012-11-26T09:00:51Z | - |
dc.date.issued | 1995 | en_US |
dc.identifier.citation | Neuroreport, 1995, v. 7 n. 1, p. 169-172 | en_US |
dc.identifier.issn | 0959-4965 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/175736 | - |
dc.description.abstract | A cysteine to serine substitution at amino acid 23 in the 5-HT(2C) receptor gene alters the pharmacological properties of the protein. We investigated this polymorphism in subjects with schizophrenia resistant to conventional neuroleptic drugs, and analysed our data for allelic association between the disease state or clinical response to the atypical antipsychotic drug, clozapine. Ninety percent of subjects who had one or more 5-HT(2C)ser alleles (19/21) were classified as clozapine responders compared with 59% (84/141) without this allele (χ2 = 7.7, p = 0.005), suggesting that this mutation is a predictor of good response to clozapine. There was no association between schizophrenia and the 5-HT(2C)ser allele, but our results indicate that the 5-HT(2C) receptor may contain the major site of action through which clozapine mediates its antipsychotic effects. | en_US |
dc.language | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.neuroreport.com | en_US |
dc.relation.ispartof | NeuroReport | en_US |
dc.subject | 5-HT2c receptor | - |
dc.subject | Amino acid substitution | - |
dc.subject | Association study | - |
dc.subject | Clozapine | - |
dc.subject | Genotype | - |
dc.subject | Schizophrenia | - |
dc.subject.mesh | Alleles | en_US |
dc.subject.mesh | Antipsychotic Agents - Therapeutic Use | en_US |
dc.subject.mesh | Base Sequence | en_US |
dc.subject.mesh | Case-Control Studies | en_US |
dc.subject.mesh | Clozapine - Therapeutic Use | en_US |
dc.subject.mesh | Double-Blind Method | en_US |
dc.subject.mesh | Genetic Variation | en_US |
dc.subject.mesh | Genotype | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Molecular Sequence Data | en_US |
dc.subject.mesh | Polymorphism, Genetic | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Receptors, Serotonin - Genetics | en_US |
dc.subject.mesh | Schizophrenia - Drug Therapy - Genetics | en_US |
dc.subject.mesh | Serotonin Antagonists - Therapeutic Use | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.title | Association between clozapine response and allelic variation in the 5-HT(2C) receptor gene | en_US |
dc.type | Article | en_US |
dc.identifier.email | Sham, P: pcsham@hku.hk | en_US |
dc.identifier.authority | Sham, P=rp00459 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1097/00001756-199512000-00041 | - |
dc.identifier.pmid | 8742444 | - |
dc.identifier.scopus | eid_2-s2.0-0029551796 | en_US |
dc.identifier.volume | 7 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 169 | en_US |
dc.identifier.epage | 172 | en_US |
dc.identifier.isi | WOS:A1995TX36900041 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Sodhi, MS=7004463507 | en_US |
dc.identifier.scopusauthorid | Arranz, MJ=7006010757 | en_US |
dc.identifier.scopusauthorid | Curtis, D=14633020700 | en_US |
dc.identifier.scopusauthorid | Ball, DM=7202703810 | en_US |
dc.identifier.scopusauthorid | Sham, P=34573429300 | en_US |
dc.identifier.scopusauthorid | Roberts, GW=7403400681 | en_US |
dc.identifier.scopusauthorid | Price, J=7404020184 | en_US |
dc.identifier.scopusauthorid | Collier, DA=26642980600 | en_US |
dc.identifier.scopusauthorid | Kerwin, RW=7102904567 | en_US |
dc.identifier.issnl | 0959-4965 | - |